This will be a randomized, partial-blind, placebo-controlled, single dose, cross-over trial
investigating the effect of GSK1349572 on cardiac repolarization as compared to placebo in
healthy adult males and females. Approximately 42 subjects will be enrolled in this study and
will be admitted to the clinic for three separate dosing sessions. Subjects will receive
single dose administrations of placebo, a supratherapeutic dose of GSK1349572 (250 mg), and
moxifloxacin (400 mg) in random sequence. Safety of subjects will be monitored by clinical
observation, measures of vital signs, 12-lead ECGs and clinical laboratory measurements.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Collaborator:
Shionogi
Treatments:
Dolutegravir Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination